Osimertinib plus anlotinib for advanced NSCLC with acquired EGFR T790M mutation: results from a multicenter phase II study with ctDNA analysis

Table 3 Results of univariable and multivariable Cox regression analysis of overall survival

Variable	Univariable regression			Multivariable regression
Variable	HR	95% CI	P value^*	HR	95% CI	P value
Age, years (≥ 65/< 65)	0.87	0.32–2.36	0.784
Sex (male/female)	0.76	0.27–2.20	0.617
Smoking status (former/never)	1.32	0.43–4.08	0.755
ECOG-PS (1/0)	1.04	0.37–2.89	0.943
EGFR mutation type (L858R/ex19 del)	1.63	1.01–2.67	0.049	1.57	0.92–2.66	0.098
Brain metastasis (yes/no)	2.91	1.08–7.87	0.035	4.63	1.39–15.45	0.013
Liver metastasis (yes/no)	0.38	0.05–2.89	0.347
Bone metastasis (yes/no)	2.15	0.82–5.61	0.120
Pleural metastasis (yes/no)	0.92	0.26–3.25	0.380
Adrenal gland metastasis (yes/no)	9.49	0.99–91.25	0.051
aEGFR mutations at baseline (detectable/non-detectable)	0.81	0.19–3.58	0.786
T790M mutation at baseline (detectable/non-detectable)	0.89	0.31–2.53	0.821
TP53 alteration at baseline (detectable/non-detectable)	1.94	0.72–5.25	0.193

^*Significant P values < 0.05 are in bold. ECOG-PS, the Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor gene; Ex19 del, exon 19 deletion; aEGFR mutations, activating EGFR mutations

ISSN: 1741-7015